A clinical study to evaluate the effectiveness and safety of taking Lignisul MSM for the treatment of pain in osteoarthritis of the knee and hip is to be undertaken by the Carolwood Corporation.
The effectiveness of Lignisul MSM will be directly compared to naproxen, the non-steroidal anti-inflammatory drug (NSAID) which is widely prescribed throughout the world.
Although naproxen is now a generic drug because the patent has run out, it is still a costly treatment and newer drugs like Celebrex and Vioxx can be prohibitively expensive for those seeking pain relief.
Even though the majority of patients use NSAIDs for pain control, side effects such as dyspepsia, gastrointestinal bleeding, exacerbation of blood pressure and renal failure can limit their use. Therefore new treatments are actively sought. In addition, there is a very real trend among patients with rheumatological problems to seek alternative therapies, which are thought to be safer and more natural, for pain relief.
The prime goal of the 12 month study is to enable patients and physicians to make informed decisions when considering the use of Lignisul MSM to alleviate the pain of osteoarthritis, the most common form of arthritis in patients over 40 years of age and which is commonly found in the knee and hip joints.
It will have strict inclusion criteria including disease duration, pain intensity, previous use of NSAIDs or analgesic therapies and age. The ultimate aim will be to demonstrate the effectiveness of Lignisul MSM compared to naproxen, offering sufferers an alternative therapy that works, improving their physical function and quality of life.
Lignisul MSM is a nutritional supplement that provides biologically active sulphur. It is manufactured by the Carolwood Corporation and is an all-natural, ultrapure MSM. Recent pilot studies of methyl-sulfonyl-methane (MSM) indicate that it may offer a safe, non-toxic way to help ease the pain of arthritis and other inflammatory conditions in humans.